However, the relationship between baseline IL-6 levels in treatment-naïve patients with advanced pancreatic cancer and their subsequent prognosis, as well as the effectiveness of systemic chemotherapy and its connection with systemic inflammatory markers, remains largely unexplored. This evidence concerns the gene IL6 and pancreatic neoplasm.